These findings advocate for CMI’s integration into primary care risk stratification protocols.[34] The identified threshold (CMI ≥ 0.182) could guide personalized interventions – structured weight loss,[35] Mediterranean diets, or PPAR-γ agonists – to mitigate visceral adiposity and dyslipidemia. The gene discussed is PPARG; the disease is metabolic syndrome.